The United States Food and Drug Administration is recommending that use of Avastin (bevacizumab) be suspended in the treatment of breast cancer because of too severe side effects with too little efficacy. FDA officer Dr. Janet Woodcock comments.
InsideSurgery Medical Information Blog
Details of surgical procedures, pathophysiology, signs and symptoms, and treatment of medical diseases,medical and surgical eponyms, and surgeons and surgery in the news
The United States Food and Drug Administration is recommending that use of Avastin (bevacizumab) be suspended in the treatment of breast cancer because of too severe side effects with too little efficacy. FDA officer Dr. Janet Woodcock comments.
Spreading the word… thanks for the heads up